Literature DB >> 1426216

Easy bruising as a side-effect of inhaled corticosteroids.

V H Mak1, R Melchor, S G Spiro.   

Abstract

We wished to determine the prevalence of easy bruising in patients taking inhaled corticosteroids (ICS) compared with those who do not. Differences in age, dosage and duration of use of ICS between patients who bruised and those who did not were also investigated. Confidential questionnaire surveys were conducted over a 6 month study period amongst patients attending a respiratory out-patient clinic and taking regular ICS, and a control group of patients attending non-respiratory clinics and not taking any form of corticosteroids. Patients with bleeding disorders or taking oral steroids, non-steroidal anti-inflammatory drugs or anticoagulants were excluded from the study. Questionnaires from 202 respiratory patients using ICS (group A) were compared with 204 non-ICS patients (Group B) of similar age and sex distribution. Significantly more patients in Group A reported easy bruising than in group B (47 vs 22%, relative risk 2.18, 95% confidence interval (95% CI) 1.62-2.94), and it was the commonest reported symptom. In Group A, the patients that reported easy bruising tended to be older (61 vs 52 yrs), on higher daily dosages (1,388 vs 1,067 micrograms) and had been taking inhaled corticosteroids for longer (55 vs 43 months) than non-bruisers. Overall, females reported easy bruising more frequently than males in both groups. However, comparing Group A with Group B, males taking ICS had a higher relative risk for bruising than females (males, relative risk 5.80, 95% CI 2.38-14.13; females, relative risk 1.80, 95% CI 1.32-2.44).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1426216

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

Review 1.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 2.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 4.  Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.

Authors:  D M Newnham
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Categorizing asthma severity: an overview of national guidelines.

Authors:  Gene L Colice
Journal:  Clin Med Res       Date:  2004-08

6.  Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis.

Authors:  Songshi Ni; Zhenxue Fu; Jing Zhao; Hua Liu
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

7.  Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands.

Authors:  T W de Vries; J J de Langen-Wouterse; E van Puijenbroek; E J Duiverman; L T W de Jong-Van den Berg
Journal:  Eur J Clin Pharmacol       Date:  2006-04-01       Impact factor: 2.953

8.  Risk of adverse gastrointestinal events from inhaled corticosteroids.

Authors:  Richard A Hansen; Wanzhu Tu; Jane Wang; Roberta Ambuehl; Clement J McDonald; Michael D Murray
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

9.  Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function.

Authors:  P H Brown; A P Greening; G K Crompton
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

10.  Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Authors:  Zia R Tayab; Tom C Fardon; Daniel K C Lee; Kay Haggart; Lesley C McFarlane; Brian J Lipworth; Günther Hochhaus
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.